Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial ( HiSCO ‐01)
Präoperative versus postoperative Chemotherapie mit CAPOX plus Bevacizumab bei resektablen kolorektalen Lebermetastasen: randomisierte Phase-II-Studie (HiSCO-01)
Annals of Gastroenterological Surgery · 2025-11 · 9 (6) · 1253-1262
DOI: 10.1002/ags3.70035 ↗Auf einen Blick
In der randomisierten Phase-II-Studie HiSCO-01 wurde präoperative mit postoperativer CAPOX-Bev bei resektablen kolorektalen Lebermetastasen verglichen. Die Therapieeinhaltung war präoperativ numerisch höher.
Fragestellung
Verbessert eine präoperative gegenüber einer postoperativen CAPOX-plus-Bevacizumab-Therapie die Outcomes bei resektablen kolorektalen Lebermetastasen?
Methode
Randomisierte Phase-II-Studie mit präoperativer versus postoperativer CAPOX-plus-Bevacizumab-Therapie über 8 Zyklen; primärer Endpunkt war die Treatment Compliance Rate.
Ergebnisse
Von 81 eingeschlossenen Patient:innen waren 76 geeignet. TCR: 89,2 % in der Präop-Gruppe vs. 71,8 % in der Postop-Gruppe (p = 0,06). Schwere Nebenwirkungen ähnlich; biliäre Fistel häufiger postoperativ.
Schlussfolgerung der Autor:innen
Beide Strategien mit CAPOX-Bev waren sicher anwendbar; präoperative Chemotherapie zeigte numerisch eine höhere TCR als postoperative Chemotherapie. Der multimodale Ansatz ist vielversprechend.
Kernaussagen
- TCR: 89,2 % präoperativ vs. 71,8 % postoperativ
- Schwere therapiebedingte Nebenwirkungen ähnlich
- Biliäre Fistel postoperativ häufiger
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Annals of Gastroenterological Surgery, online erschienen am 09.05.2025. Verfasst von Yuji Takakura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological and Transplant Surgery Hiroshima Prefectural Hospital Hiroshima Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
NCCN and ESMO guidelines recommend up to 6 months of perioperative oxaliplatin‐based chemotherapy for patients with resectable colorectal liver metastases (CRLM). However, the optimal sequencing and chemotherapy regimen remain unclear.
Methods
We conducted a randomized phase II trial, HiSCO‐01, to compare the outcomes of preoperative (Preop‐group) and postoperative chemotherapy (Postop‐group) with eight cycles of CAPOX plus bevacizumab (CAPOX‐Bev) in patients with resectable CRLM. The primary endpoint was the treatment compliance rate (TCR), defined as the percentage of patients who received at least six cycles of CAPOX‐Bev and underwent R0 resection.
Results
Of the 81 patients enrolled, 76 patients were eligible. TCR was 89.2% in Preop‐group and 71.8% in Postop‐group ( p = 0.06). The overall incidence of chemotherapy‐related Grade 3 or higher adverse events was similar between the two groups. The postoperative complication rate was comparable except that biliary fistula developed significantly higher in Postop‐group. The 3‐year progression‐free survival and 5‐year overall survival rates were 32.2% and 60.5% in Preop‐group, respectively, and 38.5% and 57.2% in Postop‐group, respectively.
Conclusion
Both preoperative and postoperative CAPOX‐Bev were safely administered, and preoperative chemotherapy showed numerically higher TCR than postoperative chemotherapy. This multimodal approach is highly promising for treating resectable CRLM. Trial Registration UMIN Clinical Trial Registry: UMIN000003783
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological and Transplant Surgery Hiroshima Prefectural Hospital Hiroshima Japan.
- Division of Clinical Oncology Hiroshima Prefectural Hospital Hiroshima Japan.
- Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan.
- Department of Surgery Chugoku Rosai Hospital Kure Japan.
- Department of Surgery National Hospital Organization Higashihiroshima Medical Centre Higashi-Hiroshima Japan.
- Department of Surgery JR Hiroshima Hospital Hiroshima Japan.
ORCID-Profile: Hiroyuki Egi, Manabu Shimomura, Tsuyoshi Kobayashi, Hideki Ohdan
Zitieren
APA
Takakura, Y., Shinozaki, K., Ikeda, S., Egi, H., Hirata, Y., Shimomura, M., Oshiro, T., Hinoi, T., Sumitani, D., Nakahara, M., Yoshimitsu, M., Honmyo, N., Kobayashi, T., Tanaka, J., Ohdan, H., & Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) (2025). Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial ( HiSCO ‐01). Annals of Gastroenterological Surgery, 9(6), 1253-1262. https://doi.org/10.1002/ags3.70035
Vancouver
Takakura Y, Shinozaki K, Ikeda S, Egi H, Hirata Y, Shimomura M, et al. Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial ( HiSCO ‐01). Annals of Gastroenterological Surgery. 2025;9(6):1253-1262. doi:10.1002/ags3.70035
BibTeX
@article{Takakura2025,
author = {Takakura, Yuji and Shinozaki, Katsunori and Ikeda, Satoshi and Egi, Hiroyuki and Hirata, Yuzo and Shimomura, Manabu and Oshiro, Takafumi and Hinoi, Takao and Sumitani, Daisuke and Nakahara, Masahiro and Yoshimitsu, Masanori and Honmyo, Naruhiko and Kobayashi, Tsuyoshi and Tanaka, Junko and Ohdan, Hideki and Hiroshima Surgical Study Group of Clinical Oncology (HiSCO), Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)},
title = {Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial ( HiSCO ‐01)},
journal = {Annals of Gastroenterological Surgery},
year = {2025},
volume = {9},
number = {6},
pages = {1253--1262},
doi = {10.1002/ags3.70035}
}
EUVIMED